Dr Jennifer Martin Talks About the Effectiveness of Cognitive Behavioral Treatment for Insomnia

In this video, Jennifer Martin, PhD, Assistant Professor, UCLA, David School of Medicine, discusses how the effectiveness of cognitive behavioral treatment for insomnia among patients with dementia compare with current pharmacologic strategies.

Related Videos

Related Content

Advertisement

May 22nd 2025

Can GLP-1 Receptor Agonists Curb Cancer? Study Links Drugs to Reduced Risk in Obesity-Related Cases

Mary Caffrey

Drugs first approved to treat diabetes, which later became a top sellers to aid weight loss, are associated with reduced risk of obesity-related cancer.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

May 22nd 2025

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

Rose McNulty

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

May 20th 2025

Mepolizumab Reduces COPD Exacerbations in Patients With Eosinophilic Inflammation

Hayden E. Klein

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD).

May 20th 2025

FIBRONEER-ILD: Novel PDE4B Inhibitor Slows FVC Decline in Progressive Pulmonary Fibrosis

Hayden E. Klein

Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic therapy.

Related Content

Advertisement

May 22nd 2025

Can GLP-1 Receptor Agonists Curb Cancer? Study Links Drugs to Reduced Risk in Obesity-Related Cases

Mary Caffrey

Drugs first approved to treat diabetes, which later became a top sellers to aid weight loss, are associated with reduced risk of obesity-related cancer.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

May 22nd 2025

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

Rose McNulty

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

May 20th 2025

Mepolizumab Reduces COPD Exacerbations in Patients With Eosinophilic Inflammation

Hayden E. Klein

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD).

May 20th 2025

FIBRONEER-ILD: Novel PDE4B Inhibitor Slows FVC Decline in Progressive Pulmonary Fibrosis

Hayden E. Klein

Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic therapy.